secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001683168-24-004800
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals raises $3.1M via warrant exercise at $5.45/share; issues new warrants
--------------------------------------------------------------------------------

- Gross proceeds ~$3.1M from cash exercise of 545,286 existing warrants at reduced price of $5.45/share (original range $324-$9.72).
- Holders pay additional $0.125 per new warrant for aggregate $136,321; total gross proceeds include this amount.
- New Series C (583,098 shares, 5.5-yr term) and Series D (507,474 shares, 18-mo term) warrants issued, exercise price $5.45.
- H.C. Wainwright acts as exclusive placement agent; receives 7.5% cash fee, $35k non-accountable expenses, and 40,896 warrants.
- Net proceeds to be used for working capital and general corporate purposes; offering closed July 12, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824004800/0001683168-24-004800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824004800/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer